- 2020 (46) ▼
- 2019 (41) ▼
- 2018 (21) ▼
- 2017 (10) ▼
AVROBIO has announced that the first patient has been dosed in their Phase 1/2 GuardOne trial of AVR-RD-02, AVROBIO’s investigational gene therapy for Gaucher disease type 1.
Our CEO Tanya Collin-Histed says "This is exciting news for the Gaucher community as Gene Therapy is finally being investigated to evaluate the safety and efficacy in a clinical trial."
The study is actively recruiting in Australia and Canada and plans to open additional clinical sites in the U.S. and Israel by the end of 2020.
For the full press release, visit here